



Laval, QC, Canada



SITE HEAD

Luc Gagnon
VP, Vaccine Sciences

Laval is the mothership site of Nexelis, a Q² Solutions Company, with a history of success in developing vaccine technology for a broad array of infectious diseases. We boast a 25-year legacy in the field, featuring a history of collaborations with prestigious governmental and non-governmental institutions, including pharmaceutical companies, and innovative biotechnology companies.

- We work with the Bill & Melinda Gates Foundation, CEPI U.K. Vaccine Task Force, and BARDA referral lab
- We maintain strategic partnerships with United Kingdom Health Security Agency (UKHSA), Porton Down, U.K.

Key abilities

We house a broad expertise in various disease areas:

- **Respiratory**
 - Influenza, RSV, *N. meningitidis*, *S. pneumonia*, *B. pertussis*, *C. diphtheriae*, rhinovirus, coronavirus
- **Enteric**
 - *E. coli*, *Shigella* sp., *C. difficile*, rotavirus, *Salmonella* sp.
- **Zoonotic**
 - Chikungunya, Zika, Dengue, malaria, Nipah, yellow fever
- **Sexually transmitted**
 - CMV, HSV, HBV, HCV, EBV
- **Others**
 - HPV, adenovirus, AAV, CoxV, measles, mumps, rubella, varicella zoster, tetanus, *S. aureus*, LCMV, GBS, LCMV, polio, vaccinia

Laboratory

- 75,000-square-foot, state-of-the-art BSL2 laboratories and offices in our main building at 525 Blvd. Cartier West
- >1 MM tube storage (-20°C, -80°C, and LN2)
- 1,500-square-foot BSL3 new laboratory including animal facility opening Q4 2023 at Institut Armand Frappier
- High-throughput clinical testing with a capacity of 500,000 samples per year
- Various immunology *in vivo* models including rodents, canines, and nonhuman primates



Notable certifications: GCLP accreditation and R&D, in vivo: AALAC, CCAC, and OLAW

OUR STORY

1998

George Lowell, inventor of the intranasal administration of a proteosome-influenza vaccine, creates Intellivax.

2001

ID Biomedical acquires Intellivax with a group of 20 scientists whose key individuals are still with Nexelis.

2004

ID Biomedical acquires Shire's vaccine division, whose team was working in a newly built facility at 525 Blvd. Cartier West and key scientists previously with URV (Unité de recherche en vaccinologie), which was created in 1996. Core team remains at Nexelis.

2005

GSK acquires ID Biomedical R&D division in Laval, QC, and manufacturing unit in Ste-Foy, QC, and invests in automation to grow Laval's capacity and support clinical testing of strategic projects in the virology and bacteriology fields.

2015

GSK divests Laval site with approximately 55 employees to NEOMED Institute, a not-for-profit organization incubating health care ventures.

2018

Management and Ampersand Capital acquires NEOMED-LABS from NEOMED Institute with the aim to execute a high-growth strategy and build a world-class immunology-centric testing company.

2019

NEOMED-LABS, rebranded as Nexelis, acquires Pacific Biomarkers in Seattle, WA, with a 25-year legacy in the metabolic field, and PAIRimmune, a preclinical CRO developing *in vivo* and *in vitro* models in the infectious and oncologic fields. An exclusive partnership is also built with PHE Porton Down in the U.K.

2020

Nexelis acquires AIT Biosciences in Indianapolis, IN, a CRO with strong credentials in the LBA and MS fields and GSK vaccine R&D site in Marburg, Germany. Laval becomes the reference laboratory for BMGF and CEPI to support COVID-19 vaccine and therapeutic development and supports more than 50 sponsors in the area.

2021

With more than 170 people, Laval, the mothership site at Nexelis, sees its size triple in three years under Nexelis tenure.

2022

Nexelis is acquired by IQVIA/Q² Solutions. With the combination of Marburg (Germany), Raleigh-Durham (USA), Beijing (China) and Laval (Canada), Nexelis/Q² Solutions is the only company in the world with fully bridged vaccine testing capacities in North America, Europe, and APAC.



Lab equipment and techniques

- AKTA Explorer, Avant 25
- SpectraMax 5Me
- QuantStudio 7
- ForteBio Octet Red96
- Luminex X200, FlexMap
- MSD S600
- Fortessa X20
- CTL S6 Ultimate
- SpectraMax ID3
- VersaMax Envision
- Integra Systems Assist Plus, ViaFlow and ViaFill
- Vi-Cell XR
- BioTek Cytation 7
- InDevR CypherOne

About Nexelis, a Q² Solutions Company

With unrivaled expertise in immunology, five operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic, and oncologic fields. Our versatile team of scientists, working with state-of-the-art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

Contact us

Phone: +1 450.239.1605

Website: www.nexelis.com

